Welcome to our dedicated page for Thermo Fishr Sci SEC filings (Ticker: TMO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Thermo Fisher Scientific filings document operating results, material agreements, governance matters and capital-structure disclosures for a global supplier of scientific instruments, laboratory products, diagnostics, life science tools and pharmaceutical services. Recent Form 8-K reports include quarterly and annual results, acquisition-related events and definitive agreements.
The company’s proxy materials cover shareholder voting and board-governance matters. Its securities disclosures identify common stock and multiple NYSE-listed senior note classes, while Form 25 filings document removal from listing and registration for specific senior notes. The filing record also includes risk-factor and corporate disclosure categories tied to Thermo Fisher’s operating businesses and financing structure.
HARRIS C MARTIN reported acquisition or exercise transactions in this Form 4 filing.
Thermo Fisher Scientific director Harris C. Martin received a grant of 499 shares of Common Stock on May 20, 2026 at no cash cost. This compensation-related award increased his direct holdings to 9,532 shares. The filing does not report any open-market buying or selling.
THERMO FISHER SCIENTIFIC INC. director Ruby R. Chandy received a grant of 499 shares of Common Stock on May 20, 2026 at no cost as compensation. Following this award, Chandy directly holds 3,463 shares, indicating a routine, non-market acquisition rather than an open-market purchase or sale.
Thermo Fisher Scientific director Nelson Chai received a stock grant of 499 shares of Common Stock. The shares were acquired at a stated price of $0.00 per share, indicating a compensation-related award rather than an open-market purchase. Following this grant, Chai directly holds 15,316 shares of Thermo Fisher Scientific Common Stock.
Thermo Fisher Scientific reported Q1 2026 revenue of $11.01B, up 6% year over year, with organic revenue growth of 1%. GAAP operating income was $1.86B and diluted EPS rose to $4.43 from $3.98, helped by a low 4.0% effective tax rate.
The company generated free cash flow of $825M and ended the quarter with $3.25B in cash and $43.16B of total debt. It closed the $9.10B acquisition of Clario to expand clinical research offerings and agreed to sell its microbiology business for about $1.08B. Thermo Fisher also repurchased $3.0B of stock and recorded $49M of restructuring costs, with about $290M of additional actions identified, mainly in Laboratory Products and Biopharma Services.
Thermo Fisher Scientific Inc Schedule 13G: Vanguard Capital Management reports beneficial ownership of 28,008,822 shares of Thermo Fisher common stock, representing 7.53% of the class as of 03/31/2026. The filing states these holdings include securities held by Vanguard funds and managed accounts where Vanguard affiliates exercise dispositive power.
Thermo Fisher Scientific President & COO Gianluca Pettiti sold 400 shares of Common Stock in an open-market transaction. The sale occurred on April 27, 2026 at a price of $462.66 per share. The transaction was made under a Rule 10b5-1 trading plan adopted on September 12, 2025. After this sale, Pettiti continues to hold 25,050.832 shares of Thermo Fisher Scientific Common Stock directly.
Gianluca Pettiti submitted a Form 144 notice indicating 400 shares of Common Stock tied to a restricted stock vesting on 02/28/2024 are being offered for sale. The filing lists a brokerage account at Fidelity Brokerage Services LLC and shows a prior sale of 400 shares on 02/09/2026 for $216,480.00.
Thermo Fisher Scientific Inc. reported solid first quarter 2026 results, with revenue up 6% to $11.01 billion and organic revenue growth of 1%. GAAP diluted EPS rose 11% to $4.43, while adjusted EPS increased 6% to $5.44, reflecting higher operating income and slightly improved GAAP operating margin of 16.9%.
Adjusted operating income grew to $2.40 billion with an adjusted operating margin of 21.8%. Free cash flow more than doubled to $825 million. The company completed the acquisition of Clario, repurchased $3.0 billion of stock, increased its dividend by 10%, and continued launching new products and strategic collaborations.
Thermo Fisher Scientific is asking shareholders to vote on electing 11 directors, approving an advisory say‑on‑pay resolution, and ratifying its independent auditors at the 2026 virtual annual meeting. The proxy highlights 2025 results, with revenue up 4% to $44.56 billion, GAAP diluted EPS rising 7% to $17.74, adjusted EPS of $22.87, and free cash flow of $6.34 billion. The company deployed about $16.5 billion of capital, including $13 billion for M&A such as the Filtration and Separation business from Solventum and an agreement to acquire Clario, and returned $3.6 billion via buybacks and dividends, achieving 11.3% adjusted ROIC. The Board emphasizes strong governance, active refreshment, and extensive shareholder engagement after only about 36% support on the 2025 say‑on‑pay vote, leading to 2026 compensation design changes and a long‑dated, performance‑based CEO retention grant tied to relative TSR versus the S&P 500.